EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement

Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis

Hematology/Oncology and Stem Cell Therapy · 2022-07 · 15 (3) · 66-72

DOI: 10.56875/2589-0646.1024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2022-07. Verfasst von Dongni Yi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Thomas Jefferson University Sidney Kimmel Medical College, United States. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objective: CAR T-cell therapy has significantly improved the outcomes of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, most clinical trials excluded patients with central nervous system (CNS) involvement due to uncertain efficacy and safety. Material and methods: On January 1, 2022, we searched PubMed to identify all published literature associated with current commercial CAR T-cell therapies for B-NHL, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi- cel), brexucabtagene autoleucel (brexu-cel), and lisocabtagene maraleucel (liso-cel). Studies that involved patients with either primary or secondary CNS lymphoma, and evaluated response rate, adverse events (AEs), or survival were included and summarized.

Result

Herein, we summarize the results of 11 studies qualified for our inclusion criteria, reporting 58 lymphoma patients with CNS Involvement with 44 evaluable for clinical response, 25 for immune effector cell-associated neurotoxicity syndrome (ICANS) and 48 for Cytokine release syndrome (CRS). Objective response was achieved in 62% (16/26) of patients, and CR was achieved in 52% (23/44) of patients. Forty-four percent (11/25) developed ICANS, and 35% (17/48) developed severe ICANS (grade≥3). CRS was reported in 63% (15/24) of patients, while severe CRS (grade>3) was reported in 7% (3/42) of patients.

Conclusion

Based on our PubMed literature review, we conclude that CAR T-cell therapy may benefit patients with CNS lymphoma with promising response rates and acceptable AE. However, definite conclusions cannot be drawn until data with a larger sample size is available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLymphomaLymphoma, Large B-Cell, DiffuseHumansImmunotherapy, AdoptiveCytokine Release SyndromeCentral Nervous SystemT-LymphocytesReceptors, Antigen, T-CellNeurotoxicity Syndromes

Substanzen

cell-associated neurotoxicityReceptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Thomas Jefferson University Sidney Kimmel Medical College, United States.
  • Tufts University, United States.
  • Ain Shams University, Egypt.
  • Weill Cornell Medicine, United States.

Zitieren

APA

Yi, D., Gergis, M., Elgohary, G., Hsu, J., Yang, Y., Bi, X., & Gergis, U. (2022). Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. Hematology/Oncology and Stem Cell Therapy, 15(3), 66-72. https://doi.org/10.56875/2589-0646.1024

Vancouver

Yi D, Gergis M, Elgohary G, Hsu J, Yang Y, Bi X, et al. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. Hematology/Oncology and Stem Cell Therapy. 2022;15(3):66-72. doi:10.56875/2589-0646.1024

BibTeX
@article{Yi2022,
  author = {Yi, Dongni and Gergis, Mia and Elgohary, Ghada and Hsu, Jingmei and Yang, Yang and Bi, Xia and Gergis, Usama},
  title = {Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement},
  journal = {Hematology/Oncology and Stem Cell Therapy},
  year = {2022},
  volume = {15},
  number = {3},
  pages = {66--72},
  doi = {10.56875/2589-0646.1024}
}
Kostenlos starten →